In the cancer cell models that received radiotherapy or chemotherapy (nzarotamide, docetaxel and cisplatin), NEIL3 knockdown significantly reduced the sensitivity of prostate cancer cells to radiotherapy or chemotherapy but did not affect ADT resistance [69,70] (Table 1). Here, NEIL3 is linked to prostate cancer.